Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder (Q28241583)

2

0 references

Louise Levine

3

0 references

Ronald Landbloom

4

0 references

Darryle D Schoepp

5

0 references

Gary D Tollefson

Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740.

6

0 references

language of work or name

English

0 references

publication date

June 2008

0 references

published in

Neuropsychopharmacology

0 references

volume

33

0 references

issue

7

0 references

page(s)

1603-10

0 references

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301531

7 January 2021

Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301531

7 January 2021

Regulation of neurotransmitter release by metabotropic glutamate receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301531

7 January 2021

Neurotransmission in the rat amygdala related to fear and anxiety

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301531

7 January 2021

Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301531

7 January 2021

Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301531

7 January 2021

Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301531

7 January 2021

Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301531

7 January 2021

Open-label trial of riluzole in generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301531

7 January 2021

Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxioly

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301531

7 January 2021

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301531

7 January 2021

An examination of 26,168 Hamilton Depression Rating Scale scores administered via interactive voice response across 17 randomized clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301531

7 January 2021

The metabotropic glutamate receptors: structure and functions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301531

7 January 2021

The neuroanatomical basis of anxiety

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301531

7 January 2021

REPLICATION OF FACTORS OF PSYCHOPATHOLOGY IN INTERVIEW, WARD BEHAVIOR AND SELF-REPORT RATINGS OF HOSPITALIZED DEPRESSIVES

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301531

7 January 2021

Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301531

7 January 2021

LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301531

7 January 2021

LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301531

7 January 2021

LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301531

7 January 2021

Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301531

7 January 2021

Metabotropic glutamate receptors as novel targets for anxiety and stress disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301531

7 January 2021

Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301531

7 January 2021

The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301531

7 January 2021

Group II metabotropic glutamate receptors within the amygdala regulate fear as assessed with potentiated startle in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301531

7 January 2021

The hospital anxiety and depression scale

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301531

7 January 2021